Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 255,300 shares, a growth of 45.4% from the September 15th total of 175,600 shares. Currently, 6.3% of the company’s stock are sold short. Based on an average daily trading volume, of 4,560,000 shares, the days-to-cover ratio is currently 0.1 days.

Virax Biolabs Group Price Performance

NASDAQ VRAX traded up $0.11 during trading on Monday, hitting $1.90. 58,185 shares of the company traded hands, compared to its average volume of 1,988,397. Virax Biolabs Group has a 12 month low of $0.60 and a 12 month high of $9.00. The business has a fifty day simple moving average of $2.80 and a 200 day simple moving average of $1.66.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.